Clinical Trial Update: Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance [Phase 3]

View source ↗

Summary

A Phase 3 multicenter randomized study of imatinib (Glivec) in advanced gastrointestinal stromal tumors expressing C-kit was interrupted after 5 years, comparin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Sarcoma

Drugs mentioned

• Glivec (imatinib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Sarcoma, Gastro-intestinal Stromal Tumors (GIST) | Phase 3 | Status: COMPLETED